EGFR and cancer: For example, it has been reported that cancers from patients with lung adenocarcinoma that harbored mutations within the tyrosine kinase domain of the HER1 gene often responded initially to TKI drugs such as Gefitinib and Erlotinib [14, 15] but usually developed drug-resistance later [16–18].